Pragmatic Phase II Clinical Trial
Also known as: pragmatic Phase II trial, real-world Phase II trial, Phase II pragmatic RCT, Phase IIb pragmatic trial
A pragmatic Phase II clinical trial is an early-to-mid-stage interventional study that evaluates a new treatment's preliminary efficacy and safety under conditions that approximate real-world clinical practice rather than tightly controlled experimental settings. It sits between pure explanatory Phase II trials and large pragmatic Phase III confirmatory trials, prioritising practical feasibility and clinical relevance while still generating the signal needed to justify further development.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Use a pragmatic Phase II design when a treatment has shown mechanistic or early-phase biological plausibility and you need a preliminary effectiveness estimate in a population and setting that resembles intended clinical use — particularly when sponsor resources or patient populations make a fully controlled explanatory Phase II impractical, or when the intervention is already partially embedded in care (e.g., repurposed drug, complex behavioural intervention). Do NOT use when the primary goal is still purely mechanistic (pharmacokinetic/pharmacodynamic profiling), the sample size required for a pragmatic heterogeneous population would eliminate the cost and speed advantages of a Phase II design, or when regulatory agencies require strictly explanatory Phase II data as a condition for Phase III approval.
Strengths & limitations
- Generates effectiveness data that are more transferable to real clinical practice than those from tightly controlled explanatory trials.
- Broader eligibility criteria improve recruitment speed and reduce selection bias relative to explanatory Phase II designs.
- Early identification of feasibility, adherence, and implementation barriers that would only surface at Phase III otherwise.
- Can leverage routinely collected electronic health data, reducing cost and participant burden.
- Provides a stronger rationale for Phase III investment by confirming the intervention works in a representative population.
- Greater heterogeneity in the patient population increases variance, requiring larger sample sizes than classic explanatory Phase II trials.
- Flexibility in intervention delivery can introduce treatment variation that complicates interpretation of the efficacy signal.
- Pragmatic outcome measures (e.g., administrative records, patient-reported outcomes) may be less precise or subject to differential ascertainment than laboratory endpoints.
- Regulatory agencies may not accept pragmatic Phase II data as a formal basis for Phase III authorisation without supplementary explanatory data.
- Balancing pragmatic breadth with sufficient internal validity to produce a trustworthy efficacy signal is a design tension that requires explicit methodological decisions.
Frequently asked
How does a pragmatic Phase II differ from a Phase III pragmatic trial?
A pragmatic Phase II trial is still an early-to-mid-phase study: its primary objective is signal detection — establishing preliminary evidence of efficacy or activity and characterising safety — rather than definitive proof of efficacy. Phase III pragmatic trials are powered for confirmatory evidence and are typically much larger. Phase II pragmatic designs accept greater uncertainty in exchange for speed and cost savings at the development decision point.
What is PRECIS-2 and do I need to use it?
PRECIS-2 is a validated nine-domain rating wheel that helps trial designers explicitly specify how pragmatic or explanatory each component of their trial is, from eligibility criteria to primary outcome. Its use is not mandatory but is strongly recommended: it makes design choices transparent, supports peer review, and helps communicate the trial's real-world relevance to funders, clinicians, and regulators.
Can pragmatic Phase II trials satisfy regulatory requirements for Phase II evidence?
This depends on the jurisdiction and therapeutic area. Regulatory agencies such as the FDA and EMA generally require adequate and well-controlled studies; pragmatic designs may need to demonstrate that flexibility in delivery did not compromise internal validity. Pre-submission meetings with regulators are advisable when a pragmatic Phase II is intended to support an IND, NDA, or marketing authorisation pathway.
Is intention-to-treat analysis always appropriate in a pragmatic Phase II?
Intention-to-treat (ITT) is the primary analysis framework for pragmatic trials because it reflects real-world use, where patients may deviate from the protocol. However, a pre-specified per-protocol sensitivity analysis is also important to confirm that the pragmatic ITT result reflects a genuine treatment effect and not merely differential adherence. Both should be reported.
How large should a pragmatic Phase II trial be?
Sample size depends on the primary outcome, expected effect size, and the variance attributable to the heterogeneous pragmatic population. Because pragmatic populations are more variable than explanatory trial populations, classic Phase II sample-size estimates based on homogeneous cohorts will typically underestimate the required sample. A simulation-based or pilot-data-informed power calculation that accounts for covariate variance is recommended.
Sources
- Schwartz, D., & Lellouch, J. (1967). Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Diseases, 20(8), 637–648. DOI: 10.1016/0021-9681(67)90041-0 ↗
- Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., ... & Chalkidou, K. (2009). A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology, 62(5), 464–475. DOI: 10.1016/j.jclinepi.2008.12.011 ↗
How to cite this page
ScholarGate. (2026, June 3). Pragmatic Phase II Clinical Trial. ScholarGate. https://scholargate.app/en/epidemiology/pragmatic-phase-ii-clinical-trial
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive Phase II Clinical TrialEpidemiology↔ compare
- Phase I Clinical TrialEpidemiology↔ compare
- Phase II clinical trialEpidemiology↔ compare
- Pragmatic phase III clinical trialEpidemiology↔ compare
- Pragmatic randomized clinical trialEpidemiology↔ compare
- Randomized clinical trialEpidemiology↔ compare